Paclitaxel and Mortality: The Dose Argument Is Critical

J Endovasc Ther. 2019 Aug;26(4):467-470. doi: 10.1177/1526602819857241. Epub 2019 Jun 9.

Authors

Andrew Holden¹, Ramon L Varcoe², Michael R Jaff³, Peter A Schneider⁴, Gunnar Tepe⁵, Thomas Zeller⁶

Affiliations

¹ 1 University of Auckland, Auckland Hospital, Auckland, New Zealand.
² 2 University of New South Wales, Prince of Wales Hospital, Sydney, Australia.
³ 3 Harvard Medical School, Boston, MA, USA.
⁴ 4 University of California, San Francisco, CA, USA.
⁵ 5 RoMed Klinikum, Rosenheim, Germany.
⁶ 6 University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany.

PMID: 31179816
DOI: 10.1177/1526602819857241

No abstract available

Keywords: Dose effect; drug-coated balloon; drug-eluting stent; drug-eluting technology; femoropopliteal segment; mortality; paclitaxel.

Publication types

Comment

MeSH terms

Femoral Artery*
Paclitaxel*
Randomized Controlled Trials as Topic
Stents
Treatment Outcome

Substances

Paclitaxel